SCHEMBL26529918

SCHEMBL26529918

Cc1cc(C(=O)N2CCC(CC(=O)O)CC2)nn1C

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR2E1 Q9Y466 1/20 0.53
▸ HTR2A P28223 1/20 0.49
▸ SLC9A1 P19634 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ LMNA P02545 2/20 0.44
▸ PDE2A O00408 1/20 0.43
▸ BAZ2B Q9UIF8 1/20 0.42
▸ RORC P51449 2/20 0.41
▸ MGLL Q99685 5/20 0.41
▸ RAB9A P51151 1/20 0.40
▸ PIK3CD O00329 1/20 0.39
▸ NAMPT P43490 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26529929 0.86 NR2E1 (0.47) NR2E1HTR2ASLC9A1ALDH1A1KDM4E
SCHEMBL23260468 0.79 NR2E1 (0.46) NR2E1HTR2ASLC9A1ALDH1A1KDM4E
SCHEMBL26530022 0.77 IRAK4 (0.44) NR2E1HTR2ASLC9A1ALDH1A1KDM4E
SCHEMBL26530058 0.77 NR2E1 (0.44) NR2E1HTR2ASLC9A1ALDH1A1KDM4E
SCHEMBL4336905 0.77 KMT2A (0.53) ALDH1A1RAB9A
SCHEMBL16132137 0.77 NR2E1 (0.63) NR2E1HTR2ASLC9A1ALDH1A1KDM4E
SCHEMBL12926042 0.77 NR2E1 (0.59) NR2E1HTR2ASLC9A1ALDH1A1KDM4E
SCHEMBL26530054 0.76 NR2E1 (0.43) NR2E1HTR2ASLC9A1ALDH1A1KDM4E
SCHEMBL26530078 0.76 NR2E1 (0.43) NR2E1HTR2ASLC9A1ALDH1A1KDM4E
SCHEMBL26535536 0.76 HDAC4 (0.47) NR2E1HTR2ASLC9A1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 — — US disclosed
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322715-A1 BROAD SPECTRUM ANTI-CANCER COMPOUNDS YTHDF1, YTHDF3, YTHDF2 NR2E1 2168/4885HTR2A 1643/4885SLC9A1 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback